Table 2 Correlation between serum myostatin levels and clinical characteristics.

From: Myostatin as a plausible biomarker for early stage of sarcopenic obesity

n = 80

ln myostatin

 

R

P

Age

0.21

0.0617

BMI

0.079

0.4880

WC

0.021

0.8552

WHtR

0.0056

0.9605

ABSI

−0.037

0.7419

PBF

−0.28

0.0108

SMI

0.29

0.0083

Grip strength (n = 79)

0.058

0.6123

ln AST

0.33

0.0032

ln ALT

0.30

0.0068

ln Plt

−0.20

0.0765

ln γGTP

0.17

0.1288

ln BUN

0.13

0.2461

ln Cr

0.20

0.0823

UA

0.072

0.5270

ln T-Cho

−0.092

0.4156

ln TG

−0.24

0.0298

ln HDL-C

0.041

0.7203

LDL-C

−0.032

0.7807

ln Glu

0.024

0.8343

ln HbA1c

0.28

0.0127

ln Insulin

−0.13

0.2358

ln HOMA-R

−0.12

0.2764

  1. BMI body mass index, WC waist circumference, WHtR waist-to-height ratio, ABSI a body shape index, PBF percent body fat, SMI skeletal muscle mass index, AST aspartate aminotransferase, ALT alanine aminotransferase, Plt platelet, γGTP γ-glutamyl transpeptidase, BUN blood urea nitrogen, Cr creatinine, UA uric acid, T-Cho total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Glu glucose, HbA1c hemoglobin A1c, HOMA-R homeostatic Model Assessment of Insulin Resistance. Log-transformed values were expressed with ln at the beginning. The Pearson’s correlation coefficient analysis was used for the assessment of relationship between serum myostatin levels and clinical characteristics. Bold font indicates statistical significance.
Back to article page